Rucaparib - OmicsDI

Show results for

Unknown (244)
Metabolomics (23)
Genomics (15)
Proteomics (15)
Clinical (3)
Other (1)
Transcriptomics (1)

Organisms

Schizophyllum commune H4-8 (15)
Mycobacterium tuberculosis SP7 (15)
Salmonella enterica subsp. enterica serovar Typhimurium str. T000240 (15)
Oryza sativa Japonica Group (15)
Rabbit calicivirus (15)
Crotalus durissus terrificus (15)
Eriocheir sinensis (15)
Candidatus Endoriftia persephonae (15)
Mycobacterium tuberculosis SP10 (15)
Mycobacterium tuberculosis SP13 (15)
Cotesia typhae (15)
Mycobacterium tuberculosis SP22 (15)
Cepaea nemoralis (15)
Enterobacter ludwigii (15)
Trichoderma asperellum CBS 433.97 (15)
Corynebacterium diphtheriae bv. mitis str. ISS 3319 (15)
Nakaseomyces glabratus (15)
Olea europaea (15)
Mumps virus strain Enders (15)
Chlamydomonas reinhardtii (15)
Deinococcus deserti VCD115 (15)
Lama (15)
Planorbella pilsbryi (15)
Paradendryphiella salina (15)
Wolbachia sp. wMelPop (15)
Pyricularia oryzae P131 (15)
Enterococcus mundtii CRL35 (15)
Pongo pygmaeus (15)
Peromyscus leucopus (15)
Homo sapiens (9)

Organisms

Homo sapiens (6)

Repository

MetaboLights (23)
pride (15)
ENA (8)
EGA (7)
geo (2)

Tissue

Epithelial cell (6)
Cell culture (5)
Lung neuroendocrine cell (3)
Ovarian surface epithelial cell (3)
Breast epithelium (1)
Ovarian serous carcinoma cell (1)
Mesenchymal cell (1)
Permanent cell line cell (1)

Disease

Malignant neoplasm of ovary (7)
Lung small cell carcinoma (3)
Cervix carcinoma (3)
Neoplasms (2)
Colorectal Neoplasms (1)
Peripheral primitive neuroectodermal tumor (1)
Breast cancinoma (1)
Breast cancer (1)

Technology Type

Mass Spectrometry (15)
Mass spectrometry assay (12)
Mass spectrometry (11)
Affinity purification coupled with mass spectrometry proteomics (7)
Shotgun proteomics (5)
Top-down proteomics (3)
Bottom-up proteomics (1)

Instrument Platform

Liquid Chromatography MS - negative - hilic (9)
Liquid Chromatography MS - positive - hilic (8)
Liquid Chromatography MS - positive - reverse-phase (5)
Liquid Chromatography MS - negative - reverse-phase (5)
Liquid Chromatography MS - negative - HILIC (3)
Liquid Chromatography MS - positive - HILIC (3)
Liquid Chromatography MS - positive - reverse phase (3)
Liquid Chromatography MS - negative - reverse phase (3)
Liquid Chromatography MS - alternating - hilic (2)
Liquid Chromatography MS - negative - direct infusion (1)
Liquid Chromatography MS - positive - direct infusion (1)
Liquid Chromatography MS - (1)
Liquid Chromatography MS - alternating - reverse-phase (1)

CHEBI ID

CHEBI:184111 (3)
CHEBI:34911 (3)
CHEBI:81930 (3)
CHEBI:63954 (3)
CHEBI:80751 (3)
CHEBI:191090 (3)
CHEBI:91455 (3)
CHEBI:190994 (3)
CHEBI:81744 (3)
CHEBI:183944 (3)
CHEBI:191104 (3)
CHEBI:191078 (3)
CHEBI:181598 (3)
CHEBI:191007 (3)
CHEBI:135051 (3)
CHEBI:183882 (3)
CHEBI:190975 (3)
CHEBI:183872 (3)
CHEBI:28362 (3)
CHEBI:190931 (3)
CHEBI:133600 (3)
CHEBI:190943 (3)
CHEBI:183861 (3)
CHEBI:183960 (3)
CHEBI:183845 (3)
CHEBI:191083 (3)
CHEBI:34907 (3)
CHEBI:34080 (3)
CHEBI:80705 (3)
CHEBI:184112 (3)

Metabolite Name

Rucaparib (20)
Hypoxanthine (20)
Betaine (17)
Adenosine (16)
Riboflavin (16)
Creatine (16)
Uridine (15)
Glycerophosphocholine (15)
Cytosine (14)
Adenine (14)
Cytidine (14)
Creatinine (14)
Guanine (13)
Guanosine (13)
Amprenavir (12)
Trigonelline (12)
Arginine (12)
Oleamide (12)
Histamine (12)
Stachydrine (12)
Inosine (12)
Puromycin (11)
Pro-Trp (11)
Miglitol (11)
1-oleoyl-2-myristoyl-sn-glycero-3-phosphocholine (11)
Val-Val (11)
Melibiose (11)
Pyridoxine (11)
Biocytin (11)
Xanthine (11)

First Public Date

2026 (6)
2025 (1)
2020 (1)

Study status

Terminated (2)
Active, not recruiting (1)

Study type

Interventional (3)

Release Date

2022 (43)
2021 (40)
2020 (34)
2023 (24)
2025 (23)
2018 (21)
2024 (16)
2019 (12)
2017 (11)
2016 (8)
2014 (6)
2013 (3)
2015 (2)
2026 (1)

Lab affiliation

Moffitt Cancer Center Tampa, FL, USA (8)
Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA. (2)
Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas (1)
Department of Laboratory Medicine and Pathology University of Minnesota School of Medicine (1)
Head of Proteomics & Metabolomics Facility (1)
Department of Chemical Engineering, Imperial College London, UK (1)
Drug Discovery Moffitt Cancer Center Tampa, FL, USA (1)

Publication date

2026 (17)
2025 (7)
2022 (5)
2021 (4)
2019 (4)
2024 (2)
2023 (1)

Location

United States (3)
Belgium (1)
France (1)

Keyword

Rucaparib (3)
PARPi (1)
Rare tumor (1)
CO-338 (1)
Homologous recombination (1)
DNA repair (1)
LODESTAR (1)
Germline (1)
Somatic (1)
PALB2 (1)
RAD51C (1)
RAD51D (1)
BARD1 (1)
BRIP1 (1)
FANCA (1)
RAD51 (1)
RAD51B (1)
HRR (1)
Platinum sensitive (1)
Platinum resistant (1)
Tumor agnostic (1)
Basket trial (1)
Leiomyosarcoma (1)
Ampullary carcinoma (1)
Carcinosarcoma (1)
HRD (1)
INCB057643 (1)
Myeloproliferative neoplasm (MPN) (1)
Glioblastoma multiforme (GBM) (1)
Non-Hodgkin lymphoma (1)

Previous page
1 / 31
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 31
Next page

Sort by:

Relevance

Page size

PARP Inhibitor Sensitivity in BRCA-Proficient ovarian cancer cells is regulated by the MSH6–CHAF1A axis: 2. ADP-Ribosylation

Ovarian cancer is the leading cause of gynecologic cancer-related deaths, with high-grade serous ovarian cancer (HGSOC) being the most common and lethal subtype. While BRCA1/2 mutations are established biomarkers predicting sensitivity to PARP inhibitors (PARPis), a subset of patients with BRCA-prof...

ORGANISM(S): Homo sapiens (Human)

2026-08-21 | PXD067891 | Pride

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.

Not available

S-EPMC9652254 | biostudies-literature

Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program.

Not available

S-EPMC10314222 | biostudies-literature

Rucaparib or Physician's Choice in Metastatic Prostate Cancer.

Not available

S-EPMC10064172 | biostudies-literature

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data.

Not available

S-EPMC10416473 | biostudies-literature

Imaging PARP with [¹⁸F]rucaparib in pancreatic cancer models.

Not available

S-EPMC9399069 | biostudies-literature

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

This phase I/II trial studies the side effects and best dose of liposomal irinotecan and rucaparib when given together with fluorouracil and leucovorin calcium and to see how well they work in treating patients with pancreatic, colorectal, gastroesophageal, or biliary cancer that has spread to other...

2258499 | ecrin-mdr-crc

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.

Not available

S-EPMC6585632 | biostudies-literature

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.

Not available

S-EPMC5868608 | biostudies-literature

Direct Imaging of Drug Distribution and Target Engagement of the PARP Inhibitor Rucaparib.

Not available

S-EPMC6071506 | biostudies-literature

Previous page
1 / 31
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 31
Next page

Sort by:

Relevance

Page size

302 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

CHEBI ID

Metabolite Name

First Public Date

Study status

Study type

Release Date

Lab affiliation

Publication date

Location

Tags

Keyword

OmicsDI is part of the ELIXIR infrastructure

Tweets